References of "Lancellotti, Patrizio"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDUSP3 Phosphatase Deficiency or Inhibition Limit Platelet Activation and Arterial Thrombosis
Musumeci, Lucia ULg; Kuijpers, Marijke; Gilio, Karen et al

in Circulation (2015), 131(7), 656-68

Background A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. Better understanding of the molecular mechanisms leading to platelet ... [more ▼]

Background A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. Better understanding of the molecular mechanisms leading to platelet activation is of importance for the development of improved therapies. Recently, protein tyrosine phosphatases (PTPs) have emerged as critical regulators of platelet function. Methods and Results This is the first report implicating the dual-specificity phosphatase 3 (DUSP3) in platelet signaling and thrombosis. This phosphatase is highly expressed in human and mouse platelets. Platelets from DUSP3-deficient mice displayed a selective impairment of aggregation and granule secretion mediated through the collagen receptor glycoprotein VI (GPVI) and the C-type lectin-like receptor 2 (CLEC-2). DUSP3-deficient mice were more resistant to collagen- and epinephrine-induced thromboembolism, compared to wild-type mice, and showed severely impaired thrombus formation upon ferric chloride-induced carotid artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the molecular level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently reducing phosphorylation of PLCγ2 and calcium fluxes. To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUSP3 was developed. This compound specifically inhibited collagen and CLEC-2-induced human platelet aggregation, thereby phenocopying the effect of DUSP3 deficiency in murine cells. Conclusions DUSP3 plays a selective and essential role in collagen- and CLEC-2-mediated platelet activation and thrombus formation in vivo. Inhibition of DUSP3 may prove therapeutic for arterial thrombosis. This is the first time a PTP, implicated in platelet signaling, has been targeted with a small-molecule drug. [less ▲]

Detailed reference viewed: 85 (34 ULg)
Full Text
Peer Reviewed
See detailLa cardiomyopathie du cirrhotique : un bref aperçu
MARCHETTA, Stella ULg; DELWAIDE, Jean ULg; LANCELLOTTI, Patrizio ULg

in Revue Médicale de Liège (2015), 2

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailPulmonary Hypertension in Valvular Disease: A Comprehensive Review on Pathophysiology to Therapy From the HAVEC Group.
Magne, Julien; Pibarot, Philippe; Sengupta, Partho P. et al

in JACC. Cardiovascular imaging (2015), 8(1), 83-99

Pulmonary hypertension (PH) is a classic pathophysiological consequence of left-sided valvular heart disease (VHD). However, as opposed to other forms of PH, there are relatively few published data on the ... [more ▼]

Pulmonary hypertension (PH) is a classic pathophysiological consequence of left-sided valvular heart disease (VHD). However, as opposed to other forms of PH, there are relatively few published data on the prevalence, impact on outcome, and management of PH with VHD. The objective of this paper is to present a systematic review of PH in patients with VHD. PH is found in 15% to 60% of patients with VHD and is more frequent among symptomatic patients. PH is associated with higher risk of cardiac events under conservative management, during valve replacement or repair procedures, and even following successful corrective procedures. In addition to its usefulness in assessing the presence and severity of VHD, Doppler echocardiography is a key tool in diagnosis of PH and assessment of its repercussion on right ventricular function. Assessment of pulmonary arterial pressure during exercise stress echocardiography may provide additional prognostic information beyond resting evaluation. Cardiac magnetic resonance is also useful for assessing right ventricular geometry and function, which provide additional prognostic information in patients with VHD and PH. [less ▲]

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailElevated heart rate at 24-36h after admission and in-hospital mortality in acute in non-arrhythmic heart failure.
Lancellotti, Patrizio ULg; ANCION, Arnaud ULg; Magne, Julien et al

in International journal of cardiology (2015), 182C

BACKGROUND: Elevated resting heart rate is associated with worse outcomes in chronic heart failure (HF) but little is known about its prognostic impact in acute setting. The main aim of the present study ... [more ▼]

BACKGROUND: Elevated resting heart rate is associated with worse outcomes in chronic heart failure (HF) but little is known about its prognostic impact in acute setting. The main aim of the present study was to examine the relationship between resting heart rate obtained 24-36h after admission for acute non-arrhythmic HF and in-hospital mortality. METHODS AND RESULTS: We examined the association of heart rate with in-hospital mortality in a cohort of 712 patients admitted for acute HF. None of the patients had significant arrhythmias, required invasive ventilation, or presented with acute coronary syndrome or primary valvular disease. Forty patients (5.6%) died during the hospital stay. Those patients were significantly older (78+/-9 vs. 72+/-12years; p=0.0021), had higher heart rate (92+/-22 vs. 78+/-18bpm; p<0.0001), NT pro-BNP (p=0.0005), creatinine (p=0.023), were often diabetics (p=0.026) and had lower systolic and diastolic blood pressures (p<0.05). There was a significant graded relationship between the increase in mortality rate and tertile of heart rate (p<0.01). With multivariable analysis, age (p=0.037), heart rate (p<0.0001), diastolic blood pressure (p<0.001), prior ischemic heart disease (p=0.02) and creatinine (p=0.019) emerged as independent predictors of in-hospital mortality. After adjusting for predictors of poor prognosis, patients in the highest heart rate tertile had worst outcomes when compared with those in the lowest heart rate group (p=0.007). CONCLUSIONS: Higher heart rate 24-36h after admission for acute non-arrhythmic HF is associated with increased risk of in-hospital mortality. Early targeting of elevated heart rate might represent a complementary therapeutic challenge. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Peer Reviewed
See detailPoster session 3: Thursday 4 December 2014, 14:00-18:00Location: Poster area.
Gabriels, C.; LANCELLOTTI, Patrizio ULg; Van De Bruaene, A. et al

Poster (2014, December)

Detailed reference viewed: 13 (5 ULg)
Peer Reviewed
See detailPoster session 1: Wednesday 3 December 2014, 09:00-16:00Location: Poster area.
Romano, G.; D'ancona, G.; Pilato, G. et al

Poster (2014, December)

Detailed reference viewed: 12 (4 ULg)
Peer Reviewed
See detailOral Abstract session: Stress echo in clinical practice: Friday 5 December 2014, 08:30-10:00Location: Agora.
Magne, J.; Donal, E.; Dulgheru, R. et al

Conference (2014, December)

Detailed reference viewed: 14 (1 ULg)
Peer Reviewed
See detailPoster session 4: Friday 5 December 2014, 08:30-12:30Location: Poster area.
Uejima, T.; Itatani, K.; Nakatani, S. et al

Poster (2014, December)

Detailed reference viewed: 7 (2 ULg)
Peer Reviewed
See detailPoster session 6: Saturday 6 December 2014, 08:30-12:30Location: Poster area.
Henri, C.; DULGHERU, Raluca Elena ULg; Magne, J. et al

Poster (2014, December)

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailClub 35 Poster session 2: Thursday 4 December 2014, 08:30-18:00Location: Poster area.
Voilliot, D.; Magne, Jm; DULGHERU, Raluca Elena ULg et al

Poster (2014, December)

Detailed reference viewed: 10 (1 ULg)
Peer Reviewed
See detailPoster session 5: Friday 5 December 2014, 14:00-18:00Location: Poster area.
Henri, C.; DULGHERU, Raluca Elena ULg; Magne, J. et al

Poster (2014, December)

Detailed reference viewed: 17 (7 ULg)
Full Text
Peer Reviewed
See detailRecommandations européennes concernant la prise en charge de l'embolie pulmonaire.
MELISSOPOULOU, Maria ULg; ANCION, Arnaud ULg; LANCELLOTTI, Patrizio ULg

in Revue Medicale de Liege (2014), 69(11), 594-599

Detailed reference viewed: 36 (5 ULg)
Full Text
Peer Reviewed
See detailLe médicament du mois Combinaison fixe périndopril-indapamide-amlodipine (Triplixam®) pour le traitement de l’hypertension artérielle
SCHEEN, André ULg; LANCELLOTTI, Patrizio ULg; KRZESINSKI, Jean-Marie ULg

in Revue Médicale de Liège (2014), 69(10), 565-570

Triplixam® is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension : perindopril, an ... [more ▼]

Triplixam® is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension : perindopril, an angiotensin converting enzyme inhibitor, indapamide, un diuretic whith thiazide-like effects but also specific properties, and amlodipine, a long-acting calcium antagonist of the dihydropyridine family. The potential synergic action allows better control of blood pressure with once daily administration, while limiting the incidence of adverse events. Various presentations with different dosages are available to facilitate individualized therapy. Warnings and precautions for use of every molecule should of course be respected. Such a fixed dose combination should contribute to limit clinical inertia and to improve therapeutic compliance. [less ▲]

Detailed reference viewed: 90 (1 ULg)
Full Text
Peer Reviewed
See detail2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Elliott, Perry M.; Anastasakis, Aris; Borger, Michael A. et al

in European heart journal (2014), 35(39), 2733-79

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.
Ryden, Lars; Grant, Peter J.; Anker, Stefan D. et al

in Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease (2014), 11(3), 133-73

Detailed reference viewed: 15 (1 ULg)